Advertisement

Topics

Search Results for "Pharmac Cost Of Sativex In New Zealand"

09:12 EDT 27th June 2016 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

PHARMAC proposes listing of Harvoni and Viekira Pak

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on two proposals to list…

NZ’s PHARMAC calls for proposals on insulin glargine supplies

New Zealand’s Pharmaceutical Management Agency, PHARMAC, this morning announced is interested in considering…

NZ’s PHARMAC considers listing of Amgen’s Sensipar

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list cinacalcet…

NZ’s PHARMAC consults on proposed listing of Praxbind and Pradaxa

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal involving…

NZ’s PHARMAC to list Janssen’s Sirturo and Sylvant for rare disorders

New Zealand’s Pharmaceutical Management Agency PHARMAC announced this morning the approval of an agreement…

NZ’s PHARMAC to fund Sensipar; consult on Sirturo, Sylvant

New Zealand’s Pharmaceutical Management Agency PHARMAC announced today its decision to list cinacalcet…

Medicines New Zealand says PHARMAC model needs updating

“We are outraged that the Minister of Health has today confirmed NZ$30 million [~$20 million] of PHARMAC’s…

PHARMAC proposal to list new respiratory products

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to relating…

Matching PubMed Articles

New Zealand patients.

Objective The aim of the present study was to better understand the views and experiences of New Zealand patients on switching between brands of prescription medicines and on alternative funding optio...

Is cost-related non-collection of prescriptions associated with a reduction in health? Findings from a large-scale longitudinal study of New Zealand adults.

To investigate whether cost-related non-collection of prescription medication is associated with a decline in health.

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.

Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel ap...

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ(9)-tetrahydrocannabinol acting through CB1 receptors.

Sativex®, an equimolecular combination of Δ(9)-tetrahydrocannabinol-botanical drug substance (Δ(9)-THC-BDS) and cannabidiol-botanical drug substance (CBD-BDS), is a licensed medicine that may be pr...

The first reported case of equine Nocardioform placentitis in New Zealand.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement